388 related articles for article (PubMed ID: 31226134)
21. Hyperkalaemia in people with diabetes: occurrence, risk factors and outcomes in a Danish population-based cohort study.
Thomsen RW; Nicolaisen SK; Adelborg K; Svensson E; Hasvold P; Palaka E; Pedersen L; Sørensen HT
Diabet Med; 2018 Aug; 35(8):1051-1060. PubMed ID: 29790603
[TBL] [Abstract][Full Text] [Related]
22. Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes.
Xu Y; Fu EL; Trevisan M; Jernberg T; Sjölander A; Clase CM; Carrero JJ
Am Heart J; 2022 Jan; 243():177-186. PubMed ID: 34610282
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.
Epstein M; Reaven NL; Funk SE; McGaughey KJ; Oestreicher N; Knispel J
Am J Manag Care; 2015 Sep; 21(11 Suppl):S212-20. PubMed ID: 26619183
[TBL] [Abstract][Full Text] [Related]
24. Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice.
De Nicola L; Di Lullo L; Paoletti E; Cupisti A; Bianchi S
J Nephrol; 2018 Oct; 31(5):653-664. PubMed ID: 29882199
[TBL] [Abstract][Full Text] [Related]
25. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes.
Collins AJ; Pitt B; Reaven N; Funk S; McGaughey K; Wilson D; Bushinsky DA
Am J Nephrol; 2017; 46(3):213-221. PubMed ID: 28866674
[TBL] [Abstract][Full Text] [Related]
26. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
27. Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis.
Jiménez-Marrero S; Cainzos-Achirica M; Monterde D; Vela E; Enjuanes C; Yun S; Garay A; Moliner P; Corbella M; Jovells-Vaqué S; Alcoberro L; Pons-Riverola A; Ramos-Polo R; Morillas H; Gómez-Hospital JA; Comin-Colet J
Eur J Intern Med; 2024 Jul; 125():89-97. PubMed ID: 38548513
[TBL] [Abstract][Full Text] [Related]
28. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
Mårup FH; Peters CD; Christensen JH; Birn H
BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
[TBL] [Abstract][Full Text] [Related]
29. Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes.
Gilligan S; Raphael KL
Adv Chronic Kidney Dis; 2017 Sep; 24(5):315-318. PubMed ID: 29031358
[TBL] [Abstract][Full Text] [Related]
30. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
Rosano GMC; Tamargo J; Kjeldsen KP; Lainscak M; Agewall S; Anker SD; Ceconi C; Coats AJS; Drexel H; Filippatos G; Kaski JC; Lund L; Niessner A; Ponikowski P; Savarese G; Schmidt TA; Seferovic P; Wassmann S; Walther T; Lewis BS
Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):180-188. PubMed ID: 29726985
[TBL] [Abstract][Full Text] [Related]
31. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Abnormalities of Potassium Homeostasis in CKD.
Palmer BF; Clegg DJ
Adv Chronic Kidney Dis; 2017 Sep; 24(5):319-324. PubMed ID: 29031359
[TBL] [Abstract][Full Text] [Related]
33. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
34. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
35. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
Gwoo S; Kim YN; Shin HS; Jung YS; Rim H
Nephron Clin Pract; 2014; 128(3-4):381-6. PubMed ID: 25572273
[TBL] [Abstract][Full Text] [Related]
36. The positive predictive value of a hyperkalemia diagnosis in automated health care data.
Raebel MA; Smith ML; Saylor G; Wright LA; Cheetham C; Blanchette CM; Xu S
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1204-8. PubMed ID: 20878650
[TBL] [Abstract][Full Text] [Related]
37. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
38. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
[TBL] [Abstract][Full Text] [Related]
39. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.
Buysse JM; Huang IZ; Pitt B
Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443
[TBL] [Abstract][Full Text] [Related]
40. Management of Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor: Strategies to Maintain Chronic Kidney Disease Patients with Type II Diabetes on Therapy.
Mahmud HA; Palmer BF
Cardiorenal Med; 2024; 14(1):191-201. PubMed ID: 38513618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
